Abstract
Over the past decade, several trials have questioned the efficacy of vasodilator therapy in acute heart failure (AHF) in the absence of uncontrolled hypertension. In this article, we provide a unique review of the most valuable four trials that present the role of vasodilator therapy in the management of patients with AHF.These four trials have evaluated the efficacy of different types of vasodilators such as nesiritide, ulatritide, and serelaxin in the setting of AHF. Also, we compared comprehensive vasodilator therapy versus standard therapy to see if there is any effect on mortality and re-hospitalization.
Highlights
BackgroundHeart failure has a major impact on the morbidity and mortality of patients in the United States and across the world
We provide a unique review of the most valuable four trials that present the role of vasodilator therapy in the management of patients with acute heart failure (AHF)
The 2019 American Heart Association (AHA) report demonstrated that heart failure cost the nation an estimated $30.7 billion in 2012 [2]
Summary
Heart failure has a major impact on the morbidity and mortality of patients in the United States and across the world. The 2019 American Heart Association (AHA) report demonstrated that heart failure cost the nation an estimated $30.7 billion in 2012 [2]. This total includes the cost of health care services, medication, and lost productivity. The World Bank estimated the global economic loss at $108 billion per year [3]. This number may underestimate the true scale of disease as there is a considerable population with asymptomatic left ventricular (LV) systolic dysfunction
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
